



## Senzime at the Innovation Pavilion

**Uppsala, August 9, 2017. Senzime AB (publ) has been selected to exhibit at the Innovation Pavilion at The MedTech Conference in San José, California September 25-27. Ten innovative companies has been given this opportunity by AdvaMed.**

The MedTech Conference is the global summit for medical technology industry leaders and the largest annual gathering of medical technology professionals in North America. The MedTech Conference powered by AdvaMed will bring together representatives from more than 1,000 companies for business development, presentations on innovative technology and networking with policymakers, business executives and industry leaders.

AdvaMed, The Advanced Medical Technology Association, is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and digital health technologies.

*“I am thrilled that we have received the opportunity to display our cutting-edge technology at the Innovation Pavilion. We will be able demonstrate TetraGraph and its single-use electrodes TetraSens to a large portion of key opinion leaders from the US”,* says Lena Söderström, CEO at Senzime.

Welcome to meet us at booth #1218.

### For further information, please contact:

Lena Söderström, CEO

Tel: +46-70-816 39 12 email: [lena.soderstrom@senzime.com](mailto:lena.soderstrom@senzime.com)



### TO THE EDITORS

#### About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. [www.senzime.com](http://www.senzime.com)